A retrospective, post-marketing multicenter study of efficacy and safety of polatuzumab vedotin in combination with bendamustine and rituximab for the treatment of relapsed and refractory aggressive B-cell non-Hodgkin lymphoma
Latest Information Update: 19 Jan 2022
At a glance
- Drugs Bendamustine (Primary) ; Polatuzumab vedotin (Primary) ; Rituximab (Primary)
- Indications B-cell lymphoma; Diffuse large B cell lymphoma
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 19 Jan 2022 New trial record